|
業務類別
|
Biotechnology |
|
業務概覽
|
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase. |
| 公司地址
| 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024 |
| 電話號碼
| +1 858 224-9600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kiorapharma.com |
| 員工數量
| 13 |
| Dr. Brian M. Strem, PhD |
Director, President and Chief Executive Officer |
美元 582.13K |
30/04/2026 |
| Ms. Melissa Tosca, C.P.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 344.78K |
30/04/2026 |
|
|
| Dr. Praveen Tyle, PhD |
Chairman of the Board |
30/04/2026 |
| Ms. Lisa Walters Hoffert |
Independent Director |
30/04/2026 |
| Dr. David A. Hollander, M.D. |
Independent Director |
30/04/2026 |
| Mr. Aron Shapiro |
Director |
30/04/2026 |
| Dr. Brian M. Strem, PhD |
Director, President and Chief Executive Officer |
30/04/2026 |
| Ms. Erin Parsons |
Independent Director |
30/04/2026 |
| Mr. Carmine Stengone |
Independent Director |
30/04/2026 |
|
|
|
|
